Bionomics pops 12 per cent on brokerage recommendation

Bionomics Ltd. popped 12 per cent on Wednesday 16th November after a bullish speculative buy recommendation. We suggest there are safer ways to make a buck or two.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bionomics Ltd. (ASX:BNO) popped 12 per cent on Thursday 17th November after Bell Potter published a bullish speculative buy recommendation.

Bionomics closed the day at $0.42 up from $0.375. Speculative investors are no doubt hoping for a repeat of the spectacular 42% three day jump in Bionomics share price that occurred back in April, when Bell Potter initiated coverage. That jump from $0.50 to $0.72 was followed by an incredibly volatile 3.5 months. The volatility finally  gave way to the slow downward spiral of the last 3.5 months.

The Bell Potter report spans 38 pages, though we suspect most investors didn't look any further than this overly optimistic valuation.

We value Bionomics on a probability-weighted DCF basis at $1.41 base case and $2.51 optimistic case. Our $1.50 price target sits at the low point of this range.

We made similar calculations on the back of an envelope and can now unreliably inform the entire Australian biotech industry is around 70-80% undervalued.

The most important sentence in the entire overly optimistic recommendation is the very final one. Sadly few investors ever read that or realise what it means.

Bell Potter Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document.

On past form we would be surprised if Bell Potter did not receive  commissions, underwriting or fees for what can be best described as marketing. As the following three year chart shows the only thing making rapid progress at Bionomics is its losses.

We'd suggest there might be safer ways to make a buck than a highly speculative investment in Bionomics. Buyer beware.

Are you worried about the situation in Europe? Read This Before The Next Market Crash is The Motley Fool's free report. Be prepared. Click here to request your free copy, before it's too late.

Article authorised by Bruce Jackson. No contributors to this article owned shares in any companies mentioned. The Motley Fool has a de-risked disclosure policy.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »